Multimedia·Mar 22, 2021

Watch: Michael Kremer World Bank Keynote Lecture: Conference on Vaccinating South Asia

On March 4, Michael Kremer presented his recent research during the South Asia Economic Policy Network Conference’s keynote lecture. The 7th South Asia Economic Policy Network Conference on Vaccinating South Asia convened leading scholars to present papers related to vaccine policy in the region.

 

About the Conference

Vaccinating South Asia against COVID-19 will provide the surest path to economic recovery, but many practical issues in vaccinating South Asia remain to be addressed. Preliminary estimates suggest that accelerating the end of the pandemic through a vaccine by only one month could have benefits of $43 billion in South Asia alone. Good news regarding at least three vaccine candidates has encouraged hope globally that the pandemic may be close to an end, but many issues remain, including bottlenecks in supply chains and production, issues related to allocation of scarce vaccine and equity, and the fiscal impacts that purchasing and delivering a COVID-19 vaccine broadly will have on South Asian governments.

Related People

More on this topic

BFI Data Studio·May 14, 2024

Return to Office and the Tenure Distribution

Austin Wright, David Van Dijcke, and Florian Gunsilius
Return-to-office (RTO) mandates drive employees away from firms, with senior employees leaving at the highest rates, likely leading to significant human capital costs in terms of output, productivity, innovation, and competitiveness for the companies implementing strict RTO policies.
Topics: COVID-19, Employment & Wages
Research Briefs·Mar 7, 2024

What Drives Inflation? Lessons from Disaggregated Price Data

Elisa Rubbo
US inflation in the early phases of the COVID pandemic was entirely driven by disruptions in supply and demand across industries, whereas most of the subsequent increase in consumer prices is driven by aggregate demand.
Topics: COVID-19, Monetary Policy
Research Briefs·Feb 1, 2024

Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development

Rachel Glennerster, Thomas Kelly, Claire T. McMahon, and Christopher M. Snyder
A universal COVID-19 vaccine that is effective against existing and future variants could provide the United States population with $1.5–$2.6 trillion more in social value than variant-specific boosters. The social value of a universal vaccine eclipses the cost of incentivizing...
Topics: COVID-19